Discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients.
Woburn, MA
Joined April 2022
- Tweets12
- Following7
- Followers30
- Likes2
We’re pleased to be included in a @BioCentury article highlighting the potential of ionizable lipids in the #LNP space. Thank you BioCentury for featuring us and our approach to developing tissue-targeted LNPs for delivery of #genomicmedicines: bit.ly/3W7AN98
Excited for #ASGCT24 in Baltimore! Check out our poster (#1273) today for insights on tissue-targeted lipid nanoparticles delivering mRNA in pulmonary, oncology, and vaccine programs. Read our press release here: prnewswire.com/news-releases…
Congratulations to Hopewell's founder and Chief Technology Officer, Qiaobing Xu, on being named a Senior Member of the National Academy of Inventors. Dr. Xu's pioneering research at Tufts University serves as the foundation for Hopewell's novel tissue-targeted LNP platform.
Professor Qiaobing Xu of the Department of Biomedical Engineering was one of six Tufts faculty members named Senior Members of the National Academy of Inventors. bit.ly/3UQO9ra
ALT Professor Qiaobing Xu of the Department of Biomedical Engineering in his lab.
Hopewell Therapeutics, Inc. retweeted
Professor Qiaobing Xu of the Department of Biomedical Engineering was one of six Tufts faculty members named Senior Members of the National Academy of Inventors. bit.ly/3UQO9ra
ALT Professor Qiaobing Xu of the Department of Biomedical Engineering in his lab.
Last week, Haishan Li, our Director of Chemistry & Process Development, represented Hopewell at the @HansonWade Next Generation Lipid-Based Nanoparticles Delivery Summit. He gave an excellent presentation on “Advancing Genomic Medicine with ttLNP delivery system.” #ttLNP
Join us in celebrating our incredible interns on #NationalInternDay! Their hard work, fresh perspectives and passion for innovation inspire us all. We’re proud to support their interests in #science and pave the way for the next generation of #STEM leaders.
Excited to have been interviewed by @BiotechTVHQ following our Seed Financing announcement yesterday! Our team is proud to be advancing next generation lipid nanoparticles for targeted delivery of #genomicmedicines.
Hopewell Therapeutics raised $25M today to develop targeted genomic medicines. The CEO tells us about it and explains the science behind next-generation LNPs. Full video: biotechtv.com/post/louis-bre…
We’re thrilled to announce our Seed Financing of $25 million to advance next generation #LNPs for targeted delivery of #genomicmedicines. The funding will enable us to advance the development of genomic medicines based on our #ttLNP platform. Learn more: bit.ly/3NemwnI
Exciting News!
We're expanding the facilities at our Woburn location in order to support our rapidly growing pipelines, teams, and dreams!
#WeDeliverHopeAndWellness
Want to work at the world's fastest-growing biotech start-up?
Check out our open positions at Hopewell-TX.com
Our Boston-based biotechnology raises the tides of life through a new class of mRNA therapies, using organ and cell-specific biodegradable lipid nanoparticles (LNPs) to address unmet medical needs, including immuno-oncology and regenerative medicine. #SavePatientsAroundTheWorld